Publications by authors named "F Vico"
Article Synopsis
- Atopic dermatitis (AD) affects about 14.8% of adolescents and can negatively impact their sleep, academic performance, mood, self-esteem, and social interactions.
- Upadacitinib was recently approved for treating moderate-to-severe AD in adolescents 12 years and older, and this real-world study aimed to assess its effectiveness and safety.
- The study found significant improvements in the severity of AD among patients treated with upadacitinib over 52 weeks, with most achieving substantial reductions in symptoms and good overall safety outcomes.